Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elite Pharma Inc (OP: ELTP )

0.1800 -0.0040 (-2.17%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 380,911
Open 0.1877
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1840
Today's Range 0.1698 - 0.1877
52wk Range 0.0302 - 0.2100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE

Performance

YTD
+29.22%
+29.22%
1 Month
+42.52%
+42.52%
3 Month
+21.62%
+21.62%
6 Month
+14.65%
+14.65%
1 Year
+429.41%
+429.41%

More News

Read More
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Via ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
Via ACCESSWIRE
Small Stocks, Big Potential: 7 Penny Stocks Poised for Major Gains in 2024
Via InvestorPlace
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Via ACCESSWIRE
7 Penny Stocks With Promising Potential Catalysts in 2024
Via InvestorPlace
Q4 Stock Predictions: 7 Penny Stocks Ready to Roar Into 2024
Via InvestorPlace
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Via ACCESSWIRE
7 Up-and-Coming Penny Stocks to Put on Your Must-Buy List
Via InvestorPlace
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
7 OTC Stocks to Buy With Boatloads of Potential
Via InvestorPlace
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.